摘要
目的评估信必可都保治疗持续性哮喘的临床疗效和耐受性。方法采用随机、开放、平行对照研究方法,42例患者分为使用信必可都保组和使用普米克都保+奥克斯都保组,观察临床症状、肺功能变化和不良事件发生情况。结果两组药物都可改善患者的哮喘症状和按需使用缓解药的情况,但信必可都保组改善更快(P<0.05)。肺功能方面,两组患者第1s用力呼气量(FEV1)都有所提高,但两组之间无差别;信必可都保组对晨间呼气峰流速(PEFam)、夜间呼气峰流速(PEFpm)提高显著快于普米克都保+奥克斯都保用药组(P<0.05)。两组不良事件的发生率无差别(P>0.05)。结论信必可都保和普米克都保+奥克斯都保联合用药都具有良好的疗效和安全性,但信必可都保改善更快,使用更方便。
Objective To evaluate the efficacy and tolerability of symbicort turbuhaler in the treatment of persistent asthma. Methods In this open, randomized, parallel-group trial, 42 patients received symbicort turbuhaler or pulmicort turbuhaler plus oxis turbuhaler via separate inhalers, we investigated clinical symptoms, lung function and adverse-events. Results Improvement in asthma symptoms and rescue medication were observed in the two groups, improvement in symbicort turbuhaler group is earlier than the control group(P <0.05). Both groups got improvement in forced expiratory volume in 1 s (FEV1) , and there was no difference between the two groups. Symbicort turbuhaler made rapid improvement in morning peak expiratory flow (PEFam) and evening peak expiratory flow (PEF-pm) compared to the control group(P <0.05). The two groups were similar in terms of adverse-events (P > 0. 05). Conclusion Both symbicort turbuhaler and pulmicort turbuhaler plus oxis turbuhaler have good efficacy and safety. Symbicort turbuhaler provides more rapid improvement and more convenience when compared to control treatment.
出处
《上海第二医科大学学报》
CSCD
北大核心
2005年第1期74-76,共3页
Acta Universitatis Medicinalis Secondae Shanghai
